Crucell N.V.
AMS:CRXL ISIN:NL0000358562
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
News
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (September 18, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it has signed an exclusive, commercial license agreement with North Carolina-based Talecris Biotherapeutics for an undisclosed and specific protein to be produced using the PER.C6® cell line.
Crucell N.V. (AMS:CRXL) Leiden, The Netherlands (August 26, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it intends to move Dukoral® and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites within the Crucell organization, resulting in additional cost savings beyond 2011.
Crucell N.V. (AMS:CRXL) Total revenue and other operating income increased by 51% to €59.6 million, compared to €39.4 million in the second quarter of 2007. Solid gross margins of 36% and significantly reduced net loss for the second quarter to €7.9 million compared to €18.2 million in Q207. 2008 full year guidance reiterated: total revenue and other operating income growth of 20% in constant currencies[1]; higher margins; positive cash flow.
Crucell N.V. (NASDAQ:CRXL) Leiden, The Netherlands (August 5, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the second quarter of 2008 on Tuesday, August 12, 2008 at 07:45 Central European Time (CET).
Crucell N.V. (NASDAQ:CRXL) Leiden, The Netherlands/Parsippany, USA, 25 June 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Avid Bioservices, Inc. of Tustin, California to join their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved contract manufacturer (CMO) for licensees of the PER.C6® cell line located in the western U.S. Avid is the first U.S.-based contract manufacturer to be awarded this status.
Crucell N.V. (NASDAQ:CRXL) Heerlen/Leiden, The Netherlands, 16 June 2008 - DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announce another breakthrough in the production of IgG antibodies using PER.C6® technology. By employing the PER.C6® human cell line and proprietary XD(TM) technology, a record yield of over 27 grams per liter has been achieved. In March 2008 a yield of 15 grams per liter was reported. This milestone is the new manufacturing paradigm for mammalian cell culture to produce protein products effectively, where the industry has struggled to date with low yields and unstable platforms. This record surpasses all other production systems including those previously set by PER.C6® technology itself.
Crucell N.V. (NASDAQ:CRXL) 2007 Financial Statements Adopted; All Resolutions Approved
###
4,948 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 10) (Last 30 Days: 47) (Since Published: 4948)
